Accessibility Menu
Akebia Therapeutics logo

Akebia Therapeutics(NASDAQ) AKBA

Market Cap$338.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-95%
5 Year-49%
1 Year-64%
1 Month+14%
$1.26
-0.4%
-0.01Today
Akebia Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 1.262026-07-29
Akebia Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 1.262026-07-22
1 month+13.51%USD 1.112026-06-29
3 month-8.7%USD 1.382026-04-30
Year to date-21.74%USD 1.612025-12-31
1 year-64.1%USD 3.512025-07-29
3 year-20.25%USD 1.582023-07-28
5 year-48.99%USD 2.472021-07-30
Since inception-95.24%USD 26.702014-03-20

Akebia Therapeutics Financials at a Glance

Market Cap

$338.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$232.40M

Net Income (TTM)

-$20.51M

EPS (TTM)

-$0.08

P/E Ratio

-16.32

Dividend

$0.00

Beta (Volatility)

1.55 (High)

Price

$1.26

Volume

504,024.636

Open

$1.24

Previous Close

$1.26

Daily Range

$1.24 - $1.28

52-Week Range

$0.82 - $3.79

Estimated Earnings Date

Aug 6, 2026

AKBA News

Foolcom-Featured.png

Akebia (AKBA) Q2 Revenue Jumps 43%

Motley Fool Markets TeamAug 7, 2025
Physician monitoring patients onscreen vitals

Why Shares of Akebia Therapeutics Were Up Tuesday

James HalleyMay 23, 2023
Dialysis

Why Akebia Therapeutics Stock Is Soaring Today

Keith SpeightsAug 5, 2021
GettyImages-521072395

Why Akebia Therapeutics Stock Is Plunging Today

Prosper Junior BakinyFeb 25, 2021
Man looking at line chart going through floor

Why Akebia Therapeutics Stock Is Crashing Today

Keith SpeightsSep 3, 2020
Anemia on small whiteboard

Why Akebia Therapeutics Stock Is Crushing It Today

Keith SpeightsMay 5, 2020
high growth (2)

2 Small-Cap Stocks That Could Double Your Money

George Budwell, PhDApr 18, 2020
Black and white of two test tubes

Why Akebia Therapeutics Stock Sank Today

Keith SpeightsMar 10, 2020
Page 1

AKBA: Motley Fool Moneyball Superscore

50

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Akebia Therapeutics

Akebia helps people who have serious kidney problems. Its medicines manage health issues like low red blood cell counts and high mineral levels. These treatments help patients feel better while they receive regular dialysis.

Managing Kidney Disease Needs

  • Auryxia: Oral medicine for controlling phosphorus in dialysis patients and treating iron deficiency anemia in others with chronic kidney disease.
  • Vafseo: Tablet for treating anemia in adults on dialysis; it works by helping the body make more red blood cells.
  • Riona: Ferric citrate product sold in Japan by a partner to treat high phosphorus levels and iron deficiency.

Strategic Moves and Deals

  • Acquired clinical-stage drug AKB-097 from Q32 Bio in November 2025 to expand into rare kidney disease treatments.
  • Ended a licensing deal with CSL Vifor in July 2024 to regain full U.S. commercial rights for its medicine Vafseo.
  • Secured an exclusive global license from Cyclerion in June 2021 for praliciguat, a drug candidate for kidney conditions.
  • Faced the market entry of a generic version of Auryxia from Teva Pharmaceuticals Ltd. in March 2026.

What Sets the Company Apart?

The company operates as a fully integrated biotech firm that handles both the scientific discovery and the sale of its own drugs. It maintains global reach through deep partnerships with international pharmaceutical leaders like Otsuka and Mitsubishi Tanabe Pharma.

By the Numbers

  • Total revenue was $53.5 million in Q1 2026, down 6.6% from $57.3 million in Q1 2025.
  • Net income fell to a loss of $9.1 million in Q1 2026, worsening by 248.1% from the previous year.
  • Free cash flow reached negative $21.2 million in Q1 2026, a 55.9% deepening in losses compared to Q1 2025.
  • Operating income dropped to a loss of $4.7 million in Q1 2026, worsening by 134.7% year-over-year.

Bottom Line

Akebia has evolved from a research-focused startup into a commercial-stage company with two flagship kidney treatments. While it faces new competition from generic drug makers, its focus on licensing new experimental therapies supports its long-term product pipeline.

AI Generated • May 12, 2026

Industry

Biotechnology

Sector

Health Care

Employees

194

CEO

John P. Butler, MBA

Website

www.akebia.com

Headquarters

Cambridge, MA 02142, US

AKBA Financials

Key Financial Metrics (TTM)

Gross Margin

80.87%

Operating Margin

2.28%

Net Income Margin

-8.83%

Return on Equity

-62.72%

Return on Capital

9.44%

Return on Assets

-5.66%

Earnings Yield

-6.13%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$338.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

268.26M

Volume

504.02K

Avg. Volume

4.99M

Financials (TTM)

Gross Profit

$187.95M

Operating Income

$5.29M

EBITDA

-$5.76M

Operating Cash Flow

$60.37M

Capital Expenditure

-$427.00K

Free Cash Flow

$60.01M

Cash & ST Invst.

$162.64M

Total Debt

$12.50M

Akebia Therapeutics Performance Analysis

Akebia Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 292,484,00038.2%
20232023-12-31USD 194,623,000-33.5%
20242024-12-31USD 160,180,000-17.7%
20252025-12-31USD 236,196,00047.5%
Akebia Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-309.0%
Q32025-09-30-5.9%
Q42025-12-31-2.0%
Q12026-03-31-7.1%
Akebia Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.52-69.7%
20232023-12-31USD -0.28-46.3%
20242024-12-31USD -0.3318.8%
20252025-12-31USD -0.02-93.7%
Akebia Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-96.4%
Q32025-09-30122.2%
Q42025-12-31-2405.0%
Q12026-03-3126.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$53.54M

-6.6%

Gross Profit

$40.93M

-17.7%

Gross Margin

76.43%

N/A

Market Cap

$338.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.74M

N/A

Employees

194

N/A

Net Income

-$9.05M

-248.1%

EBITDA

-$13.29M

-193.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$162.64M

+43.5%

Total Debt

$12.50M

-76.9%

Accounts Receivable

$62.54M

+1.6%

Inventory

$13.00M

-34.1%

Long Term Debt

$0.00

-100.0%

Short Term Debt

$12.50M

+126.6%

Return on Assets

-5.66%

N/A

Return on Invested Capital

2.80%

N/A

Free Cash Flow

-$21.21M

-55.9%

Operating Cash Flow

-$21.21M

-56.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CMPXCompass Therapeutics, Inc.
$1.94-0.26%
PRTAProthena Corporation plc
$8.36-2.39%
FDMT4D Molecular Therapeutics, Inc.
$9.89+2.91%
ZVRAZevra Therapeutics, Inc.
$9.64-1.43%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$93.03+0.14%
MSFTMicrosoft
$446.18+0.14%
NOKNokia
$9.15+0.09%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$25.42+0.29%

Questions About AKBA

What is the current price of Akebia Therapeutics?

Akebia Therapeutics is trading at $1.26 per share.

What is the 52-week range for Akebia Therapeutics?

Over the past 52 weeks, Akebia Therapeutics has traded between $0.82 and $3.79.

How much debt does Akebia Therapeutics have?

As of the most recent reporting period, Akebia Therapeutics reported total debt of $217.92M.

How much cash does Akebia Therapeutics have on hand?

Akebia Therapeutics reported $164.35M in cash and cash equivalents in its most recent financial results.

What is Akebia Therapeutics’s dividend yield?

Akebia Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services